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A COST-EFFECTIVENESS ANALYSIS OF ACE
INHIBITOR TRANDOLAPRIL AS A
PREVENTATIVE TREATMENT OF HEART-
FAILURE PROGRESSION
Lilliu H1, Le Pen C1, Lamiraud K1,Wittenberg W2
1Clp-santé, Paris, France; 2ABBOTT GmbH &Co KG,
Ludwigshafen, Germany
OBJECTIVES: This study aimed at performing an eco-
nomic analysis in an American setting of the use of
Angiotensin Converting Enzyme (ACE) inhibitor tran-
dolapril in postinfarction patients as a preventative agent
of heart failure (HF) progression, based on the TRACE
trial’s individual data. METHODS: The TRACE study
was a prospective placebo-controlled clinical trial de-
signed to determine the long-term effect of trandolapril
in postinfarction patients with left ventricular dysfunc-
tion. 1749 patients were followed from 1992 to 1995.
Our analysis was incremental and was conducted from a
Payer Perspective in a US setting. Unit costs were attached
to the use of resources (mean costs per Diagnosis Related
Groups for hospitalizations and Average Wholesale Prices
for concomitant dugs). The primary effectiveness crite-
rion was the progression of HF as deﬁned in the clinical
trial, i.e. death from HF or hospitalization for HF or HF
necessitating open-label ACE inhibitor administration.
Uncertainty surrounding the estimate of the CE ratio was
taken into account through a non-parametric bootstrap
analysis. RESULTS: Trandolapril cost amounted to
US$550 and concomitant drugs were valued to US$2386
for trandolapril treated patients versus US$1975 for
placebo treated patients. On the other hand, hospitaliza-
tions cost was US$6671 for trandolapril patients versus
US$7979 for placebo patients. The total mean medical
cost was slightly lower in the active therapy group,
US$9607 versus US$9954, p = 0.5305. 14.04% of tran-
dolapril patients versus 19.70% of placebo patients expe-
rienced a HF progression, p = 0.003. Among 5,000
bootstrap re-samples, ACE inhibitor therapy was cost
saving in 66.7% of the cases and cost-effective in 33.3%.
The cost per avoided HF progression reached US$8860
among the samples with both cost and effectiveness 
differentials positive. CONCLUSIONS: These results
obtained in an American setting could be considered as
highly cost-effective. From a methodological standpoint,
it raises the issue of CE analysis when cost differentials
are close to zero.
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Controversy exists on the possible relaxation of the EU
regulations on the prescription drug information given
directly to patients, and Europeans have the right to voice
their opinions. OBJECTIVES: To know the views of the
Spanish population on currently available prescription
drug information and additional information they would
like access to. METHODS: A population-based telephone
survey of 1069 people over 15 and representative of the
Spanish population was conducted between February 
and March 2003. The sample was randomly selected
using proportional stratiﬁed sampling by age, gender and
Autonomous Regions, according to the Spanish National
Statistics Institute data for these variables. The question-
naire was elaborated based on a review of the legislation
and literature and on a focus group made up of repre-
sentatives who provide medical information to patients.
RESULTS: The general population normally receives
information on prescription drugs from package inserts
(75.9%), physicians (54.9%), pharmacists (17.4%) or
nurses (6.7%). Other possible sources of information
(medical journals, Internet, patient associations, family/
friends) are consulted by less than 3% of the population.
Furthermore, only 11.6% of the Spanish population state
that their physicians provide them with information on
alternative prescription drugs, so that patients feel inca-
pable of exercising their right to participate in treatment
selection. A total of 45.9% of the population would like
their physicians to provide written information (leaﬂets)
on drugs prescribed, and 52.9% demand greater access
to prescription drug information from sources other than
Health care professionals. A total of 45.6% think that
pharmaceutical companies should be allowed to provide
reliable, comprehensive and supervised information on
their prescription drugs, through leaﬂets handed out by
physicians or pharmacists. The perceived beneﬁts out-
weigh the perceived risks. CONCLUSIONS: The general
population in Spain state that they are insufﬁciently
informed on prescription drugs and are interested in
gaining access to wider high-quality information, includ-
ing that from the pharmaceutical industry.
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CHARACTERIZATION OF POLYPHARMACY
ISSUES AND SUBSEQUENT INTERVENTION IN
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OBJECTIVES: To identify and characterize medication-
related issues among elderly community-dwelling indi-
viduals with polypharmacy. To contact physicians about
advancing quality care through modiﬁcation of complex
drug regimens, either by eliminating unnecessary drugs 
or by revising therapy to reﬂect standards of practice.
METHODS: An intervention program was conducted in
retirees from a large corporation. Individuals with 9 or
